Figure 1From: Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptorDelivery of siGLO chitosan nanoparticles in vitro and in vivo. (A) HEK293 cells were transfected with 200 pmol of siGLO complexed with 5 μg of chitosan nanoparticles. Fluorescent cells containing siGLO were observed by fluorescence microscopy. HEK293 cells were also transfected with chitosan nanoparticles containing green fluorescent protein expression plasmid, pEGFP-N2, as a positive control. (B) The green fluorescence from the frozen lung sections of mice treated transdermally with siGLO or intranasal pEGFP-N2 nanoparticles was monitored by fluorescence microscopy. (C) siGLO nanoparticle cream containing 2 nmol of siGLO was spread on the backs of BALB/c nude mice, and a second dose of siGLO nanoparticles was administered 24 h later. The transdermally-delivered siGLO was detected 48 h after the initial treatment by in vivo imaging using the Xenogen IVIS system. Mice receiving intranasal pEGFP-N2 chitosan nanoparticles were included as positive control for in vivo imaging.Back to article page